GLP-1 Drugs and Disordered Eating: Why Screening Before Starting Matters

GLP-1 drugs' defining mechanism, powerful and sustained appetite suppression, is precisely why clinicians increasingly emphasize screening for disordered eating history before starting treatment, and monitoring for concerning eating patterns during it.

Why the Mechanism Raises Specific Concerns

GLP-1 receptor agonism doesn't just reduce hunger; it can substantially reduce interest in food and eating behavior generally, which is exactly the intended therapeutic effect for weight management, but carries different implications in someone with a history of anorexia nervosa, a restrictive eating disorder, or significant body image concerns tied to weight or eating control. A tool that makes restriction easier and less effortful is a specific risk factor in populations where restriction itself is the core underlying pathology, distinct from the general population the major weight-loss trials were designed around.

What Trial Exclusion Criteria Already Tell Us

The major GLP-1 weight-management trials (STEP, SURMOUNT) generally excluded participants with a history of eating disorders from enrollment — a standard and appropriate trial-design decision, but one that means the safety and outcome data these drugs are approved on doesn't directly speak to how the drugs behave in that specific population, since it was deliberately excluded from the evidence base supporting the approval.

Emerging Clinical Guidance

Professional guidance and clinical practice have increasingly moved toward incorporating eating disorder history and screening tools into the pre-GLP-1 evaluation, particularly given rising off-label and cosmetic use in populations, including younger patients and patients without obesity, where the trial-tested risk-benefit calculation applies less directly. This isn't a blanket contraindication — GLP-1 therapy isn't automatically inappropriate for someone with a past eating disorder history, particularly if it's well into remission — but it's a factor that changes the risk assessment and generally warrants closer monitoring and, ideally, coordination with a treating mental health provider familiar with that history.

Warning Signs Worth Monitoring During Treatment

• Eating substantially less than needed for basic nutritional adequacy, beyond what appetite suppression alone would explain
• Preoccupation with the medication as a tool for restriction rather than a treatment for an appropriate medical indication
• Rapid, excessive weight loss beyond what the treatment protocol anticipates
• Return or intensification of prior disordered eating thoughts or behaviors

Any of these warrant a conversation with the prescribing physician and, where relevant, a mental health provider, rather than being treated as simply a sign the medication is "working well."

Practical Takeaway

GLP-1 drugs' core mechanism, powerful appetite and food-interest suppression, is a double-edged consideration: it's the intended therapeutic effect for appropriate weight-management candidates, and a specific risk factor for people with a restrictive eating disorder history, a population largely excluded from the trials these drugs' safety data comes from. Pre-treatment screening for eating disorder history and ongoing monitoring for concerning eating patterns during treatment is increasingly considered good practice, not an optional extra step, particularly as GLP-1 use expands beyond the exact population the pivotal trials studied.